Israel’s flourishing biotech sector looks set for a good year ahead
Israeli life science companies ‘will get more done on a million dollars than a company would in the United States.’
Israeli life science companies ‘will get more done on a million dollars than a company would in the United States.’
Close to $850 million poured into Israeli firms in June 2017 to advance pharma, cybersecurity, e-commerce, autonomous-vehicle and other technologies.
Gamida Cell wins orphan drug status for stem-cell treatment; cCam Biotherapeutics gets okay for clinical trial of antibody treatment for cancers.